Topical N-acetyl-S-farnesyl-L-cysteine Inhibits Mouse Skin Inflammation, and Unlike Dexamethasone, its Effects Are Restricted to the Application Site  by Gordon, Joel S. et al.
Topical N-acetyl-S-farnesyl-L-cysteine Inhibits Mouse
Skin Inflammation, and Unlike Dexamethasone,
its Effects Are Restricted to the Application Site
Joel S. Gordon1, Peter M. Wolanin1, Arnold V. Gonzalez1, David A. Fela1, Gopal Sarngadharan1,
Karl Rouzard1, Eduardo Perez1, Jeffry B. Stock1,2,3 and Maxwell B. Stock1
N-Acetyl-S-farnesyl-L-cysteine (AFC), a modulator of G protein and G-protein coupled receptor signaling,
inhibits neutrophil chemotaxis and other inflammatory responses in cell-based assays. Here, we show
topical AFC inhibits in vivo acute inflammation induced by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and
arachidonic acid using the mouse ear model of inflammation. AFC inhibits edema, as measured by ear
weight, and also inhibits neutrophil infiltration as assayed by direct counting in histological sections and by
measuring myeloperoxidase (MPO) activity as a neutrophil marker. In addition, AFC inhibits in vivo allergic
contact dermatitis in a mouse model utilizing sensitization followed by a subsequent challenge with 2,4-
dinitrofluorobenzene. Unlike the established anti-inflammatories dexamethasone and indomethacin, AFC’s
action was restricted to the site of application. In this mouse model, both dexamethasone and indomethacin
inhibited TPA-induced edema and MPO activity in the vehicle-treated, contralateral ear. AFC showed no
contralateral ear inhibition for either of these end points. A marginally significant decrease due to AFC
treatment was seen in TPA-induced epidermal hyperplasia at 24 hours. This was much less than the 90%
inhibition of neutrophil infiltration, suggesting that AFC does not act by directly inhibiting protein kinase C.
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INTRODUCTION
The C-terminal addition of farnesyl (15-carbon side chain) or
geranylgeranyl (20-carbon side chain) polyisoprenoids is
essential to the membrane targeting of heterotrimeric and
Ras-related G proteins that mediate receptor signaling in
eukaryotic cells. This post-translational modification involves
the formation of a thioether bond between the polyisoprenoid
and a cysteine four residues from the C terminus of the
protein within a so-called CAAX-tail motif (Stimmel et al.,
1990). Prenylation is followed by membrane localization and
subsequent cleavage of the three AAX residues C-terminal to
the prenylated cysteine (Hancock et al., 1989; Reiss et al.,
1990). The resulting exposed prenylcysteine a-carboxyl is
then subject to methylation and demethylation (Clarke, 1988;
Stimmel et al., 1990). Small-molecule prenylcysteine analogs
such as N-acetyl-S-farnesyl-L-cysteine (AFC) enter cells and
compete with prenylated G proteins for sites of interaction
with receptors in the membrane or compete with prenylated
G proteins as a substrate for isoprenylcysteine methyltrans-
ferase (Volker et al., 1991b; Scheer and Gierschik, 1993;
Philips et al., 1993). In vitro studies have shown AFC and
similar analogs to be particularly effective inhibitors of
inflammatory responses, which are mediated by G-protein
coupled receptors (GPCRs) in macrophages, neutrophils, and
platelets (Volker et al., 1991a; Huzoor-Akbar et al., 1993;
Philips et al., 1993; Scheer and Gierschik, 1993). In these
assays, AFC was shown to inhibit inflammatory cell activa-
tion such as neutrophil aggregation and macrophage
chemotaxis (Volker et al., 1991a).
The targeting of GPCR and G-protein signaling in
inflammatory cell activation is a mechanism that is distinct
from the two standard classes of small-molecule anti-
inflammatories, glucocorticoids, and the classical nonsteroi-
dal anti-inflammatory drugs (NSAIDs). Glucocorticoids act by
binding to and activating their specific nuclear hormone
receptor (Evans, 1988; Gronemeyer, 1992; Beato et al.,
1995). This results in ligand-dependent transcriptional
transactivation of genes coding for negative regulators of
inflammation such as secretory leukocyte protease inhibitor
(Abbinante-Nissen et al., 1995), Clara cell 10-kDa protein
(Zhang et al., 1997b) and IL receptor antagonist (Levine et al.,
1996; Sousa et al., 1996). As an alternative mechanism of
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transrepression, the liganded receptor can interact with and
inactivate positive transcription factors such as activator
protein 1 (Diamond et al., 1990; Jonat et al., 1990; Lucibello
et al., 1990; Schu¨le et al., 1990; Yang-Yen et al., 1990) or
members of the Rel pathway, which regulate genes coding
for inflammatory mediators (Mukaida et al., 1994; Ray and
Prefontaine, 1994; Caldenhoven et al., 1995). The second
class of small-molecule anti-inflammatories, NSAIDs
are inhibitors of enzymes involved in eicosanoid synthesis
(Ferreira et al., 1971; Smith and Willis, 1971; Vane, 1971); in
particular, cyclooxygenases (reviewed in Michaelidou and
Hadjipavlou-Litina, 2005). Thus, AFC and its analogs may
have in vivo anti-inflammatory properties that distinguish it
from glucocorticoids and classical NSAIDs.
Owing to the likely inactivation of AFC in serum (Volker,
1995) and uncertainty whether sufficient amounts could
permeate the skin to affect GPCR or G-protein signaling, in
this study we set out to investigate the in vivo anti-
inflammatory activity of AFC, using a mouse model of
contact irritation. The mouse ear model has been routinely
used to test whether topically applied anti-inflammatories
inhibit the development of acute, chemically induced dermal
irritation (Van Arman, 1974; Young et al., 1983, 1984;
Carlson et al., 1985; De Young et al., 1989; Kotyuk et al.,
1993; Rao et al., 1993; Tramposch, 1999) or adaptive
immune system-based responses such as allergic contact
dermatitis (ACD) (Crowle, 1975; Garrigue et al., 1994; Saint-
Mezard et al., 2003). Moreover, this model has been used by
various groups to identify and compare the members of
differing classes of anti-inflammatory agents with multiple
mechanisms of action (reviewed in Tramposch, 1999). The
more commonly used end points of acute inflammation are
edema (Tramposch, 1999), which is assayed by increase in
ear thickness or weight and neutrophil infiltration that is
measured by assaying for the neutrophil marker myeloperoxi-
dase (MPO) (Bradley et al., 1982). By exposing both ears
to a chemical irritant while applying the test compound to
just one ear, the vehicle-treated contralateral ear serves as an
internal control (Van Arman, 1974). The validity of the results
using this internally controlled protocol, however, is depen-
dent on the demonstration that the test agent applied to one
ear does not have an effect on the contralateral ear.
We report that, in this in vivo model, topically applied
AFC inhibits development of edema and neutrophil infiltra-
tion induced by the phorbol ester 12-O-tetradecanoyl-
phorbol-13-acetate (TPA), arachidonic acid (AA) as well as
ACD edema induced by 2,4-dinitrofluorobenzene (DNFB).
Finally, we have found, unexpectedly, that AFC’s inhibition
of edema and neutrophil infiltration remains restricted to the
treated ear, whereas the glucocorticoid dexamethasone and
the NSAID indomethacin applied to one ear reduces edema
and neutrophil infiltration in the contralateral ear, even at
doses that are only partially effective on the ipsilateral ear.
RESULTS
Inhibition of edema and neutrophil infiltration by AFC
The mouse ear model was used to assess whether topically
delivered AFC could inhibit inflammation in vivo. Acute
contact inflammation has been well characterized in this
model (reviewed by Tramposch, 1999). Upon topical
application of an irritating concentration of TPA, the resulting
ear edema reaches a maximum at 5.5–6 hours (Young et al.,
1983; Gschwendt et al., 1984). Subsequent neutrophil
infiltration of the ear reaches a maximum at 20–24 hours
(Young et al., 1983; De Young et al., 1989; Rao et al., 1993)
and epidermal thickness increases substantially between 24
and 48 hours (Griffiths et al., 1988).
To measure its effect on edema, AFC was applied at
increasing concentrations to mouse ears that had been treated
simultaneously with 1.5 mg/20ml of TPA (Figure 1). The TPA-
induced increase in ear punch weight was significantly
different from baseline (untreated ear) (Table 1). In mice
receiving TPA on both ears and treated on one with 2,000mg/
20 ml AFC, the resulting weight was significantly lower than
that observed for those treated with TPA alone (Table 1).
At 2,000mg/20 ml AFC, the vehicle-treated contralateral ears
were not significantly different from those of mice treated
with TPA only (Table 1). As seen in Figure 1, AFC treatment
produced a dose-dependent inhibition of the TPA-induced
edema as compared to the control, with the maximal
reduction of edema approaching 73%, with a 50% effective
dose (ED50) of 55712 mg/20 ml (Table 2).
Although inhibition of edema establishes an in vivo anti-
inflammatory effect of AFC, previous experiments in vitro and
in cell culture suggest that neutrophil activation and
migration might also be inhibited (Philips et al., 1993; Scheer
and Gierschik, 1993; Ding et al., 1994; Volker, 1995;
Forsberg et al., 2003). Furthermore, because dermal neu-
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Figure 1. Inhibition of TPA-induced edema by AFC. A dose of 1.5 mg of TPA
in 20ml acetone containing the indicated concentration of AFC (K) was
applied to both ears of a mouse, as described in Materials and Methods,
except for 2,000 mg AFC. In that case, AFC and TPA were applied to only one
ear while the contralateral ear received only TPA (J). After 5.5 hours, a 6mm
punch was taken from each of the excised ears and immediately weighed. The
percentage inhibition was determined from the difference between the
AFC-treated ears and ears of mice treated with TPA alone divided by the
difference between ears treated with TPA alone and acetone alone. In each
independent experiment, the punch weight for a particular AFC concentration
was the average for both ears for 3–5 mice, except at 2,000 mg AFC.
Each data point represents the average value from 3 to 8 independent
experiments 7SEM. Curves were fitted to the data by the Hill,
three-parameter equation using Sigma Plot software, from which the ED50
and maximum inhibition were determined.
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trophil infiltration and edema can respond with different
specificities to different anti-inflammatory agents in this
model (Young et al., 1983; De Young et al., 1989; Rao
et al., 1993), we investigated the effect of AFC on dermal
neutrophil infiltration. Although neutrophil infiltration in
response to topical TPA reaches a maximum at 24 hours
(Young et al., 1983; De Young et al., 1989; Rao et al., 1993),
we initially assayed AFC’s effects histologically at 5.5 hours
after the application of TPA when infiltration is beginning and
the lower density of cells allows for their unequivocal
identification and counting. Fewer neutrophils were observed
in ears 5.5 hours after TPA exposure if the AFC treatment was
applied 30minutes after the TPA, and AFC reduced the
number of neutrophils in the AFC-treated ear in a dose-
dependent manner (Figure 2).
The initial histological findings showed that AFC inhibits
the infiltration of cells meeting the morphological criteria,
thus, validating the routine quantitation of neutrophil
infiltration by assaying the ear tissue biochemically for
MPO 24hours after TPA application (when neutrophil
infiltration is known to reach a maximum) (Young et al.,
1983; De Young et al., 1989; Rao et al., 1993). Our results
show TPA induced significantly greater MPO activity over the
baseline measurement of acetone-only-treated ears (Table 1).
Table 1. Summary of absolute measurements and significance
End point Irritant Treatment Acetone control Irritant control Treated ear P-value Contralateral ear P-value
Edema AA AFC 8.870.3mg (18) 15.770.6mg (18) 10.570.4mg (18) Po0.0001 15.670.8mg (18) P=0.89
— TPA AFC 8.470.1mg (33) 17.070.4mg (37) 11.270.4mg (34) Po0.0001 16.170.7mg (20) P=0.25
— — Dexa-
methasone
8.270.1mg (17) 15.170.4mg (22) 8.570.2mg (20) Po0.0001 9.570.3mg (20) Po0.0001
MPO AA AFC 571mAu/min (16) 4078mAu/min (16) 1473mAu/min (17) P=0.005 4678 mAu/min (18) P=0.55
— TPA AFC 371mAu/min (21) 172728mAu/min (22) 872mAu/min (23) Po0.0001 145720mAu/min (23) P=0.43
— — AGC 671mAu/min (9) 375750mAu/min (20) 273743mAu/min (11) P=0.12 414758mAu/min (11) P=0.61
— — Dexa-
methasone
471mAu/min (12) 162729mAu/min (30) 31710mAu/min (13) P=0.0001 61721mAu/min (13) P=0.006
— — Indomethacin 671mAu/min (12) 250735mAu/min (24) 1573mAu/min (22) Po0.0001 42718mAu/min (21) P=0.009
AA, arachidonic acid; AFC, N-acetyl-S-farnesyl-L-cysteine; AGC, N-acetyl-S-geranyl-L-cysteine; MPO, myeloperoxidase; TPA, 12-O-tetradecanoyl-phorbol-13-
acetate.
Edema was measured as the weight of a 6mm punch, whereas MPO enzyme activity measurements are represented as the change in absorbance per minute
at 460 nm. The data for the treated and contralateral ears are at the highest concentration for each agent (2,000 mg AFC, 16mg dexamethasone, 2,000 mg
AGC, and 1,000 mg indomethacin per 20ml). The number in parentheses is the number of mice used to derive each average. To compare the statistical
significance of the results, we averaged the absolute values of irritation for each individual mouse from all experiments used at the reported concentration,
calculated the SE, and used the two-tailed Student’s t-test to calculate the significance relative to the irritant control. The TPA-in-acetone vehicle-treated
contralateral ears of mice treated with dexamethasone or indomethacin exhibit significant inhibition of edema and neutrophil infiltration, but those treated
with AFC do not. A few individual mouse ears deviating more than three-fold from the mean value of their group (indicating experimental error or pre-
existing inflammation) were excluded from the analysis.
Table 2. Summary of ED50 and maximum inhibition values
End point Irritant Treatment
ED50 (lg/20ll)
(potency)
Maximum % inhibition
(activity)
Edema AA AFC 314798 100
— TPA AFC 55712 73
— — Dexamethasone 0.2570.03 100
MPO AA AFC 184782 87
— TPA AFC 118724 100
— — AGC 2779 27
— — Dexamethasone 0.4970.16 100
— — Indomethacin 1117140 100
AA, arachidonic acid; AFC, N-acetyl-S-farnesyl-L-cysteine; AGC, N-acetyl-S-geranyl-L-cysteine; MPO, myeloperoxidase; TPA, 12-O-tetradecanoyl-phorbol-
13-acetate.
The parameters extracted from calculating the data as the percentage inhibition in each separate experiment. The data were fit to the Hill equation as
described in the Materials and Methods (see Figures 1, 3, 4 and 5 and Figures S2–S4). The maximum inhibition represents the asymptotic value of the curve
fit, whereas the ED50 is the concentration of agent needed to produce half of the maximum inhibition.
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AFC was applied at increasing concentrations to mouse ears
that had been treated simultaneously with 0.8 mg/20 ml of
TPA. Mouse ears simultaneously exposed to 2,000 mg/20 ml
AFC had an MPO activity, which was highly significantly
different from that observed for treatment with TPA only.
Again, at the highest concentration of 2,000 mg/20ml AFC, the
vehicle-treated contralateral ears were not significantly
different from the TPA control (Table 1). A dose-dependent
inhibition was observed with a maximum activity approach-
ing 100% and an ED50 of 118724 mg/20ml (Figure 3 and
Table 2). Consequently, AFC was capable of inhibiting the
two hallmarks of acute contact irritation, edema, and
neutrophil recruitment, with greater potency against edema
as compared to that versus neutrophil infiltration.
Direct activation of epidermal protein kinase C (PKC) has
been shown to be involved in TPA-induced epidermal
hyperplasia, based on the effect of specific PKC inhibitors
(Griffiths et al., 1988; Reynolds et al., 1997), as well as
overexpression (Wang and Smart, 1999; Jansen et al., 2001)
and/or knockout of PKC in mouse skin (Hara et al., 2005).
Therefore we sought to determine if AFC could also inhibit
TPA-induced neutrophil infiltration independent of TPA-
induced hyperplasia. AFC was simultaneously applied with
TPA, and the effect of AFC on the TPA-induced increase in
epidermal thickness was measured at 24 hours after treatment
rather than 48 hours when the maximal increase has been
observed previously (Griffiths et al., 1988; Reynolds et al.,
1997). This end point was selected to maximize the effect on
direct TPA induction of epidermal hyperplasia and minimize
any indirect, secondary hyperplasia due to neutrophil
infiltration. A statistically significant increase in epidermal
thickness of 37% (Table 3) was observed in ears dosed with
0.8 mg/20ml of TPA (same dose used in the induction of MPO
activity). In the presence of TPA and 800 mg/20ml AFC, there
was a 22% increase in epidermal thickness (Table 3). Thus,
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Figure 2. Histology of the AFC effect on neutrophil infiltration. A dose of
2.0mg of TPA in 20 ml acetone was applied to mice on both ears. Thirty
minutes later, AFC in 20 ml acetone was applied to one ear and 20 ml of
acetone (vehicle) was applied to the contralateral ear of each mouse. After
5.5 hours, a 6mm punch from each of the excised ears was fixed in 10%
formalin. Neutrophils (-) were identified by their lobular nuclear
morphology. (a) Control animal not treated with TPA. Bar¼50 mm. (b) Skin
treated with TPA and vehicle show substantial neutrophil infiltration. (c) Skin
treated with TPA and 1,000 mg of AFC has a significantly reduced neutrophil
infiltration. (d) Quantitation of neutrophils by manual counting. The TPA and
vehicle result (0 AFC) represents the average of the contralateral ears from the
mice treated with the listed concentrations of AFC.
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Figure 3. AFC inhibition of TPA-induced MPO activity. Neutrophil
infiltration was assayed biochemically by measuring MPO activity. A dose of
0.8mg of TPA in 20 ml acetone containing the indicated concentration of AFC
(K) was applied to both ears of a mouse. For 2,000 mg AFC, both AFC and
TPA were applied to one ear while the contralateral ear received only TPA
(J). After 24 hours, a 6mm punch was taken from each of the excised ears
and frozen immediately. Enzyme assays were carried out as described in
Materials and Methods. In each independent experiment, the MPO activity for
a particular AFC concentration was the average of the values from ears for 3–5
mice. In each experiment, the percentage inhibition was determined from the
difference between the AFC-treated ears and ears of mice treated with TPA
alone divided by the difference between ears treated with TPA alone and
acetone alone. Each data point represents the average value from 3 to 4
independent experiments 7SEM. The curves were fitted to the data by the
Hill equation with two free parameters and with the maximum inhibition
fixed at 100% using the Sigma Plot software, from which the ED50 was
determined.
Table 3. Epidermal hyperplasia in response to TPA
Treatment Epidermal thickness %
20 ml acetone vehicle 10073
800 mg/20 ml AFC 10676
0.8 mg/20ml TPA 13877
0.8 mg TPA plus 800mg/20 ml AFC 12276
AFC, N-acetyl-S-farnesyl-L-cysteine; MPO, myeloperoxidase; TPA, 12-O-
tetradecanoyl-phorbol-13-acetate.
The relative increase in epidermal thickness was measured, as detailed in
the Materials and Methods at 24 h to match the end point of the MPO
assay. Each measurement represents the average of measurements on 12
mice7SE. The results are expressed as a percentage of the average
epidermal thickness measured for acetone-treated control ears. The
increase for both groups of TPA-treated ears was significantly different
from that of the control ears at the level of Po0.05 using the Student’s t-
test. The difference between the AFC-treated ear plus TPA and the TPA
alone was not significant at the 0.05 level but was at the 0.1 level.
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although AFCþTPA reduced epidermal thickness as com-
pared to that seen with TPA alone, the difference was at the
margin of statistical significance (0.104P40.05). AFC at this
concentration produced B90% inhibition of neutrophil
infiltration as measured by MPO activity (Table 2) and in
the absence of TPA did not produce a statistically significant
change in epidermal thickness (Table 3).
Although TPA-induced inflammation involves direct
activation of PKC (Liu and Heckman, 1998), downstream
effectors may possibly include members of the AA cascade
that utilize GPCRs (Kostenis, 2004). To investigate this, we
tested the ability of AFC to inhibit the inflammatory response
induced by AA in this model measuring edema and MPO
activity 1 hour post-application (Young et al., 1983; Opas
et al., 1985; De Young et al., 1989; Rao et al., 1993). Our
results show that AFC inhibits AA-induced edema and
neutrophil infiltration in a dose-dependent manner (Figures
S1 and S2). As shown in Table 1, the AA-induced ear weight
was significantly above the baseline of the acetone-only
control. AFC at 2,000mg/20 ml produced a significantly
decreased ear weight when compared to ears treated with
the AA vehicle alone (Tables 1 and 2). The maximum
inhibitory effect on AA-induced edema approaches 100%,
with an ED50 of 314798 mg/20ml (Table 2). For both end
points, AFC at the highest concentrations had no effect on
AA-induced inflammation in the contralateral vehicle-treated
ear. Thus, although AFC activity against AA was similar to
results obtained against TPA, AFC appeared to be five-fold
less potent against AA-induced edema than TPA-induced
edema. Conversely, AFC significantly reduced both AA- and
TPA-induced neutrophil infiltration with equal potency
(ED50¼ 184782 and 118724 mg/20ml, respectively; Tables
1 and 2). Consequently, these results show AFC is active
against the acute inflammatory response of two different
agents that may function through GPCR signaling. Further-
more, the difference in the ratio of potency for edema and
neutrophil infiltration was consistent with AFC acting against
different GPCR pathways activated by the different stimuli.
Similar to AFC, the prenylcysteine analog N-acetyl-
S-geranyl-L-cysteine (AGC) possesses an N-acetyl-cysteine
moiety, differing only in the length of the prenyl chain. In
previous experiments, this analog was shown to be inactive
in reducing GPCR activity and only slightly active in
inhibiting inflammatory cell responses in vitro (Volker
et al., 1991b; Philips et al., 1993). AGC was tested in the
TPA-treated mouse ear assay to compare its in vivo inhibition
of neutrophil infiltration with AFC. At 2,000mg/20 ml, our
results show that AGC produced a slight reduction in TPA-
induced MPO activity, with a maximum effect approaching
only 27% and only marginally statistically distinguishable
from the control (Tables 1 and 2, Figure S3). As with AFC,
AGC caused no significant reduction in the TPA-induced
MPO activity in the contralateral ear.
Topical AFC’s anti-inflammatory activity is restricted to the site
of application
Other anti-inflammatory agents including the glucocorticoid
dexamethasone and the cyclooxygenase inhibitor indomethacin
are also known to be active in the mouse ear model assay
(Michaelidou and Hadjipavlou-Litina, 2005), despite each
having a different mechanism of action than that postulated
for AFC (Schafer-Korting et al., 2005). To further characterize
AFC, we investigated the similarities and differences between
these anti-inflammatory agents. In preliminary studies it was
immediately apparent that both dexamethasone and indo-
methacin, but not AFC, inhibited edema and neutrophil
infiltration in both the ipsilateral ear treated with compound
and the contralateral ear that only received TPA. For
dexamethasone, we observed a dose-dependent inhibition
of TPA-induced edema that could be discerned in both the
dexamethasone-treated ears and the contralateral ears to
which only vehicle was applied (Tables 1 and 2). Inhibition of
edema can be discerned in the contralateral ear at higher
concentrations, as compared with the ipsilateral ear to which
dexamethasone was directly applied (Figure 4). A maximal
inhibition of 100% was observed in the dexamethasone-
treated ear with 50% of the maximal inhibition of edema seen
at a dose of 0.2570.03 mg/20ml (Figure 4, Tables 1 and 2).
Results also showed that dexamethasone inhibited neutrophil
infiltration (as measured by MPO activity) in both treated and
contralateral ears (Figure 5, Tables 1 and 2), with an ED50 in
the treated ear of 0.4970.16 mg.
The cyclooxygenase inhibitor, indomethacin, similar to
dexamethasone showed an inhibitory effect on TPA-induced
MPO activity of the contralateral ear to which only vehicle
was applied with an ED50 of 1117140 mg/20ml for indo-
methacin on the ipsilateral ear (Tables 1 and 2, Figure S4). In
contrast to dexamethasone, the maximum effect of indo-
methacin on the vehicle-treated contralateral ear was more
attenuated. Thus, unlike AFC, dexamethasone and indo-
methacin affect the edema and neutrophil infiltration in the
contralateral ear. Comparison of the responses of the treated
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Figure 4. Inhibition of TPA-induced edema by dexamethasone. A dose of
1.5mg of TPA in 20 ml acetone containing the indicated amount of
dexamethasone (K) was applied to one ear of a mouse, whereas 1.5mg of
TPA alone was applied to the contralateral ear (J). 5.5 hours later, a 6mm
punch was taken from each of the excised ears and immediately weighed.
Groups of 3–5 mice were used for each experiment, and each data point
represents the average value from 3 to 4 independent experiments7SEM. The
calculations and curve fitting for the dexamethasone-treated ear were as
described in for Figure 3.
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ears (Table 2) showed AFC and dexamethasone to be equally
active against both TPA-induced inflammatory end points on
the treated ear. However, based on ED50 values, the
corticosteroid was significantly more potent. AFC and
indomethacin on the other hand, exhibited approximately
equal activity and potency (Table 2).
Effectiveness of AFC applied at different times relative to TPA
To determine the effectiveness of AFC when applied at
different time intervals relative to irritant, we applied AFC an
hour before, simultaneously with and various times after TPA
treatment (Figure 6). When AFC was assayed at is highest
effective dose of 2,000mg/20ml, it was maximally effective
when applied simultaneously with TPA, or up to an hour
later. Decreasing effectiveness was observed as it was applied
with increasing intervals after TPA over the next 6 hours
(Figure 6). Dexamethasone at 6.4 mg/20ml, the highest
effective dose, was also maximally effective when applied
simultaneously with TPA or up to an hour later (Figure 6).
Dexamethasone at this high dose was effective at longer post-
treatment times than AFC (Figure 6). At a lower dose, the
duration of effectiveness of dexamethasone became some-
what shorter (data not shown).
Inhibition of ACD by AFC
An advantage of the mouse ear model is that it can be readily
adapted and utilized as a delayed-type hypersensitivity model
for ACD. Utilizing a modification of the mouse ear model
that measures inflammation in response to ACD (Crowle,
1975; Garrigue et al., 1994; Saint-Mezard et al., 2003), we
set out to investigate if AFC was also effective against
adaptive immune-based responses. Topical application of the
hapten, DNFB, followed by challenge 5 days later resulted in
ear weights that were significantly greater (14.070.7mg)
than that observed in ears from mice that had not been
sensitized but were challenged with DNFB (9.270.3mg).
Results showed that AFC applied to the ear surface
simultaneously with the DNFB challenge produced a dose-
dependent decrease in edema (Figure 7). The nearly
complete inhibition observed for 2,000mg/20ml AFC
(9.4mg70.2) was not significantly different (P¼0.66) from
the inhibition produced by 16.0 mg/20ml of dexamethasone
(9.570.4mg) and both were highly significantly different
from the control that was sensitized and then challenged with
DNFB (Po0.0001 using Student’s t-test). The lower doses of
AFC produced smaller, but still significant, reductions in the
ACD (P¼0.005 at 128mg/20 ml and P¼0.10 at 20 mg/20 ml),
showing that the effect of AFC is dose-dependent (Figure 7).
DISCUSSION
Acetylated polyprenylcysteines have previously been shown
to inhibit inflammatory cell responses in granulocytes in vitro
(Philips et al., 1993; Scheer and Gierschik, 1993; Ding et al.,
1994; Volker, 1995; Forsberg et al., 2003). However, it was
not known whether AFC’s effects in vivo would be negated
by serum inactivation (Volker, 1995), and when topically
applied, if sufficient amounts of AFC would permeate to
targets in the skin to affect inflammatory signaling pathways.
Our results establish that topically applied AFC inhibits
edema and neutrophil infiltration in vivo in the mouse ear
acute inflammation model. Importantly, AFC also inhibits
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Figure 5. Inhibition by dexamethasone of TPA-induced MPO activity. A dose
of 0.8mg of TPA in 20 ml acetone containing the indicated amount of
dexamethasone (K) was applied to one ear of a mouse, whereas 0.8mg of
TPA alone was applied to the contralateral ear (J). After 24 hours, a 6mm
punch was taken from each of the excised ears, immediately frozen and later
assayed for MPO, as described in Figure 3. Groups of 3–5 mice were used for
each experiment, and each data point represents the average value from 3 to 4
independent experiments 7SEM. The calculations and curve fitting were as
described in Figure 3.
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Figure 6. Interval dependence of AFC and dexamethasone. A dose of 1.5 mg
of TPA in 20 ml acetone was applied to each mouse ear, and agents were
applied at the indicated times relative to the application of TPA. After
24 hours, a 6mm punch was taken from each of the excised ears, frozen
immediately and assayed for MPO, as described in Figure 3. Groups of 5 mice
were used for each experiment, and each data point represents the average
value from three independent experiments 7SEM. (a) AFC time course. AFC
(20ml) at 2,000 mg/20ml in acetone was applied to one ear (K), whereas 20 ml
acetone alone was applied to the contralateral ear. (b) Dexamethasone time
course. Dexamethasone (20 ml) at 6.4 mg/20ml was applied to one ear (J),
whereas 20 ml acetone alone was applied to the contralateral ear. The
percentage inhibition was internally controlled for each AFC group using the
contralateral, TPA-treated ears of the same mice to calculate the TPA-only
value. For dexamethasone, separate groups of mice treated with TPA alone
were used as the TPA control. The percentage inhibition was determined from
the difference between the treated ears and the TPA control divided by the
difference between the TPA control and ears treated with acetone alone.
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inflammation associated with ACD in this mouse model,
showing AFC is effective against both innate and adaptive
immune-based responses. Similar to acute contact inflamma-
tion, AFC is equally effective but less potent than dexa-
methasone in reducing delayed-type hypersensitivity. In these
assays edema was used as the end point. Whether cellular
inflammation is inhibited as well await assays measuring
infiltration of T-cell lymphocytes.
Our observed in vivo inhibition data indicate AGC was
substantially less active than AFC, consistent with prior
results showing inhibition of GPCR signaling and inflamma-
tory cell activation in culture (Volker et al., 1991b; Philips
et al., 1993; Scheer and Gierschik, 1993; Ding et al., 1994;
Volker, 1995; Forsberg et al., 2003). The low activity of AGC
also clearly indicates that the N-acetyl-cysteine moiety alone,
a well-known antioxidant (Santangelo, 2003), does not play a
predominant role in the anti-inflammatory response. Overall,
our results are consistent with AFC acting in vivo by a G
protein or GPCR-dependent mechanism as it does in cell
culture models.
AA-derived eiconosoids are known to signal through
GPCRs (Kostenis, 2004). Our results showing AFC activity
toward AA-induced edema and neutrophil infiltration is thus
consistent with its in vitro modulatory activity of GPCR and
G-protein signaling (Volker et al., 1991a; Huzoor-Akbar
et al., 1993; Philips et al., 1993; Scheer and Gierschik, 1993).
The exact cellular and molecular targets triggering topical
AFC suppression of inflammation in vivo remain to be
elucidated. It is unlikely that topical AFC directly inhibits TPA
activation of migrating neutrophils. For instance, it has been
shown previously that AFC does not block TPA-initiated
events in cultured granulocytes (Ding et al., 1994; Volker,
1995). Thus, to inhibit inflammation, in vivo, topically
applied AFC most probably acts on a GPCR-activated event
that is downstream of the TPA target in the epidermis.
TPA is an analog of diacylglycerol, the activator of various
PKC isoform signaling pathways (Liu and Heckman, 1998).
The growth and differentiation of epidermal keratinocytes
have been shown to be PKC regulated (Jetten et al., 1989;
Dlugosz and Yuspa, 1993). Moreover, PKC is known to be
involved in the observed induction by TPA of epidermal
hyperplasia in vivo. (Griffiths et al., 1988; Reynolds et al.,
1997; Wang and Smart, 1999; Jansen et al., 2001; Hara et al.,
2005). We discovered AFC has a partial, but marginally
statistically significant effect, on TPA-induced epidermal
hyperplasia in the mouse at concentrations that maximally
inhibit neutrophil infiltration. The AFC-sensitive component
of the TPA-induced hyperplasia probably reflects a portion of
the hyperplasia that is induced indirectly by the inflammatory
process. Establishing unequivocally that AFC does not
directly inhibit TPA activation of PKC signaling in keratino-
cytes will require measurement of specific PKC-dependent
keratinocyte molecular markers. No direct effect by AFC on
TPA-induced hyperplasia is consistent with its lack of effect
on TPA-induced responses in neutrophils in vitro (Ding et al.,
1994; Volker, 1995). However, direct effects on keratinocyte
GPCR signaling remain an open possibility. In mice,
keratinocytes express CXCR2, a homolog to the human IL-8
receptor (Cacalano et al., 1994), which is a GPCR that
mediates inflammatory responses (Oppenheim et al., 1991).
Interestingly, CXCR2 levels are increased in keratinocyte
inflammatory diseases such as psoriasis (Kulke et al., 1998).
Consequently, AFC may contribute in modulating autocrine
or intercellular signaling by keratinocytes during inflammation.
Despite this intriguing possibility, inhibition by AFC of
inflammation is most probably due to AFC interacting with
targets downstream of PKC activation in keratinocytes.
Previous results have shown a massive increase in epidermal
neutrophil infiltration in response to TPA in transgenic mice
in which PKC-a under the regulation of a keratin-5 promoter
is overexpressed in their epidermal keratinocytes (Wang and
Smart, 1999; Cataisson et al., 2003; Cataisson et al., 2005).
These, results clearly show involvement of PKC-a in
transduction of the TPA inflammatory signal in keratinocytes.
Moreover, neutrophil infiltration is regulated by diffusible
cytokines or chemokines released by the keratinocytes in
response to TPA. Cataisson et al. (2006) have shown that in
the transgenic mouse these cytokines signal via CXCR2.
Inhibition by AFC of TPA-induced neutrophil infiltration
in non-transgenic mice suggests that AFC blocks GPCR-
activated processes such as induction of integrins (Bargatze
and Butcher, 1993; Wu et al., 1993; Laudanna et al., 1996),
which are regulated by one or more of these keratinocyte-
released factors that act directly on the neutrophils through
the CXCR2 receptor or other cytokine receptors. Alterna-
tively, keratinocyte-released mediators could affect GPCR
signaling in other dermal cells that are involved in neutrophil
attraction and extravasation. For example, induction of
vascular cell adhesion molecule-1, which is required for
neutrophil adhesion in cultured dermal vascular endothelial
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Figure 7. AFC reduces ACD. Mice were sensitized twice on the flank
challenged on the ears with DNFB as described in Material and Methods.
Dexamethasone in acetone (16 mg/20 ml) or AFC (at indicated concentration)
in H2O was applied immediately after the challenge. Twenty-four hours later,
a 6mm punch was taken from each ear and weighed. Groups of five mice
were used for each of four experiments and each data point represents the
average over the values for each animal 7SEM. The baseline of the graph
(8.3mg) represents the average mass of 6mm ear punches from matched
control mice that were not challenged with DNFB.
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cells has been shown to be inhibited by AFC (Ahmad et al.,
2002).
AFC, dexamethasone, and indomethacin have distinct
molecular targets, but are equally active in these assays. It is
interesting to note that AFC is more potent in reducing edema
than neutrophil infiltration, whereas dexamethasone has the
opposite effect, likely reflecting the utilization of different
mechanisms of action. However, topical AFC shows a
surprising pharmacodynamic difference from the other two
agents: its action is restricted to the site of topical application.
Both dexamethasone and indomethacin when applied to one
ear at doses at the upper half of the dose–response curve,
suppress edema and neutrophil infiltration in the contralateral
ear that was directly treated only with TPA in acetone. AFC,
on the other hand, does not significantly affect the edema or
neutrophil infiltration in the contralateral ear even at the
highest dose tested. The effect of dexamethasone and
indomethacin on the contralateral ear can be best explained
by their entering the systemic circulation at levels high
enough to inhibit inflammation at remote sites, and poten-
tially inhibiting neutrophil migration systemically. The
observed dose–response curve in the contralateral ear is
similar to that seen in the treated ear, but shifted to higher
concentrations, consistent with dilution in the systemic
circulation.
Systemic effects on internal organs, particularly the
adrenal gland, have been reported for topical corticosteroids
in both humans (Mackie and Bye, 2000) and mice (Reichardt
et al., 2001; Coghlan et al., 2003; Schacke et al., 2004).
These reports are the basis for several of the known concerns
about systemic adverse effects of topical glucocorticoids,
particularly in pediatric practice. It is unclear why gluco-
corticoid effects on the contralateral ear have not been
previously reported for the mouse ear assay. Perhaps it has
become routine practice that these types of compounds are
pharmacologically tested on a single ear or both ears without
the internal vehicle control (Gschwendt et al., 1984).
Furthermore, in several published reports, it is not clear if
one or both ears are being treated (Reichardt et al., 2001;
Schottelius et al., 2002; Coghlan et al., 2003; Schacke et al.,
2004). Another possibility is that the effect simply has not
been recognized when an internal control is used. The lower
baseline result would result in an artificially increased
potency (Van Arman, 1974).
Restriction of AFC’s action to the site of application could
be due to either specificity for targets localized to the skin, its
local sequestration, or inactivation within the systemic
circulation. Inactivation of AFC that penetrates the skin
within the systemic circulation is consistent with the previous
observation that the activity of AFC on cultured granulocytes
is suppressed in serum protein-containing culture medium,
presumably due its inactivation or binding by serum protein
(Volker, 1995). Because AFC as a topical anti-inflammatory is
restricted to the site of application it has a potentially strong
safety advantage. Given that AFC does not affect the
contralateral ear, we propose that AFC either does not enter
the systemic circulation, or if it does it is immediately
sequestered or metabolized. Thus, in either case, AFC will
likely not have the ability to affect GPCR signaling in any
internal organ systems.
Although the alteration of GPCR signaling in the skin other
than that required for the mounting of an inflammatory
response needs to be investigated, preliminary results suggest
that it is benign. Our results here show that there is no
observable change in epidermal thickness or morphology
upon treatment with AFC alone. Also, our preliminary
toxicology data show that AFC has no irritation potential on
its own. This is consistent with the fact that AFC is, in
essence, a naturally occurring amino acid. It has been
estimated that as much as 2% of all proteins in mammalian
cells contain a prenylcysteine modification (Casey et al.,
1989; Epstein et al., 1991). Moreover, in vivo pathways exist
for metabolizing farnesylcysteine (Zhang et al., 1997a;
Lu and Hofmann, 2006). Topical application of AFC of 16-fold
greater doses than the maximum used here (32mg dose per
ear) elicited no edema response. Mice receiving daily topical
applications of 1mg AFC for 3 months on one ear showed no
observable ill effects locally or systemically. In addition, AFC
was a nonirritant in preclinical models of acute skin irritation,
and skin sensitization in standard preclinical models (Signum
Biosciences, unpublished data).
AFC’s restriction to the site of application has unexpected
advantages for use instead of or in combination with steroids
or NSAIDs for topical treatment. The key for all treatment is to
identify more potent steroids that achieve the same activity
with a lower dose (making them less toxic), which gives a
better therapeutic index. So far, even the most potent steroids
retain substantial negative effects (Mackie and Bye, 2000).
The so-called ‘‘designer glucocorticoids’’ have been devel-
oped which selectively inhibit transrepression, without
affecting steroid hormone-mediated gene transactivation,
with the hope of inhibiting inflammation specifically
(Vayssiere et al., 1997; Reichardt et al., 2001; Coghlan
et al., 2003; Schacke et al., 2004). Although they have been
effective in animal models (Reichardt et al., 2001; Coghlan
et al., 2003; Schacke et al., 2004), they have not shown an
advantage in a human clinical use (Belvisi et al.,
2001a, 2001b). AFC, conversely, because of its restriction to
the site of application and nontoxic nature has the advantage
of being used at maximum activity without putative systemic
activity. AFC, similar to dexamethasone, is most effective
when applied simultaneously with TPA, and both lose their
effectiveness when applied at increasing intervals after the
irritant. Dexamethasone is effective over a longer interval
than AFC, but our results suggest that dexamethasone, and
presumably other steroids, would need to be applied at doses
well below 50% of maximal activity to avoid any systemi-
cally driven consequences. Thus, the opportunity arises of
using AFC at maximum activity or of using AFC in
combination with a low dose of glucocorticoids to retain
some of the steroid effects without generating adverse
systemic or dermal side effects.
In summary, we have established that topically applied
AFC inhibits both acute chemically induced inflammation
and ACD in vivo. AFC has a different predicted mechanism of
action than glucocorticoids and cyclooxygenase inhibitors,
650 Journal of Investigative Dermatology (2008), Volume 128
JS Gordon et al.
AFC Inhibits Acute Skin Inflammation in the Mouse
and unexpectedly, in contrast to these agents, AFC’s effects
are limited to the site of application. This raises the possibility
that AFC or other prenylcysteine analogs retaining AFC’s
unique properties will be novel anti-inflammatory therapeu-
tics with an improved side-effect spectrum over presently
used agents.
MATERIALS AND METHODS
Reagents
TPA, AA, dexamethasone, indomethacin, farnesyl bromide, DNFB,
and geranyl bromide were purchased from Sigma-Aldrich (St Louis,
MO). Organic solvents and reagents including acetone, acetonitrile,
ethanol, L-cysteine, methanol, methylene chloride, pentane, and
tetrahydrofuran were purchased from Fisher Scientific (Hampton,
NH). Reagent-grade water was produced using a Barnstead 18
Mohm system (Barnstead International, Dubuque, IA). Dexametha-
sone was dissolved in acetone, and the concentration measured by
diluting in MeOH, measuring the height of the absorbance at
239 nm, and using an extinction coefficient of 390 for a 1% solution.
Stocks of dexamethasone in acetone were stored at 41C for no more
than 1 week. DNFB was diluted in acetone immediately before
application. AGC was synthesized according to previously published
methods (Volker et al., 1990, 1991a). AFC and AGC were analyzed
as described below and confirmed to be of 495% purity.
Analysis of synthesized compounds
A model 1050 HPLC (Agilent Technologies, Santa Clara, CA) was
used for all high-performance liquid chromatography analysis. For
each analytical high-performance liquid chromatography run,
approximately 5 mg of AFC or AGC was injected in a volume of
5ml of acetonitrile. A 4.6 50mm Luna C-18(2) column (Pheno-
menex, Torrance, CA) was eluted with a gradient from 60% water,
40% acetonitrile with 0.05% TFA to 100% acetonitrile with 0.05%
TFA over a volume of 20ml at 2ml/minute. The absorbance at
214 nm was monitored, and the purity of the product was assessed
by taking the ratio of the integrated area of the main peak to the
integrated area of the main peak and all additional peaks in the
chromatogram.
Purity was additionally confirmed by NMR using an INOVA
series NMR (Varian, Palo Alto, CA). Approximately 50mg of AFC or
AGC was dissolved in CDCl3 and one-dimensional
1H-NMR spectra
acquired. Purity was assessed by assigning the characteristic peaks in
the product and then attributing any other peaks to impurities and
calculating the fraction of the total peak area belonging to the product.
Mice
Outbred male Swiss Webster (ICR) mice were purchased from
Hilltop Lab Animals (Scottdale, PA) or Harlan (Indianapolis, IN) and
were used for experiments between 10 and 12 weeks of age. Mice
were housed under standard conditions and experimental protocols
were approved by the Signum Biosciences Institutional Committee
on Use and Care of Animals.
Treatment protocols
For acute irritation trials, compounds were dissolved in acetone and
10 ml applied both to the dorsal and ventral surfaces of the mouse ear
(20 ml total) using a solvent pipette. On the basis of preliminary
experiments, irritant agents were applied to the ears at doses that
elicited 50% of the maximum response for each of the respective
end points. For TPA-induced edema, 1.5 mg of TPA was applied,
whereas for MPO and epidermal hyperplasia measurements, 0.8mg
of TPA was applied (except for time interval experiments where
1.5 mg TPA was used to ensure comparisons at maximal irritation).
For AA-induced edema and MPO, 2mg of AA was applied. At these
irritant doses, no change was seen in the vehicle-treated contra-
lateral ear. For edema and MPO assays, tested anti-inflammatory
agents were applied simultaneously with the irritant at the indicated
doses by dissolving them in acetone containing TPA or AA. For the
histology experiments, the AFC was applied 30minutes after the
TPA. For determining the duration of effect, agents were applied at
the times indicated in Figure 6.
It was revealed in preliminary experiments performed to establish
the effective dose range for each test compound that the assumption
that dexamethasone and indomethacin had no effect on the
contralateral vehicle-treated ear throughout the dose-dependent
range did not hold (see Results and Discussion). Thus, the use of the
vehicle-treated ear as an internal control to calculate the percentage
inhibition was not valid. Therefore, the independent percentage
inhibition at the test agent-treated ear and the vehicle-treated ear for
each dose was calculated by taking the difference between separate
control groups of mice with ears treated only with TPA or acetone to
determine the 0 and 100% inhibition points for each assay.
Adaptation of the mouse ear model to assay ACD has been
described in detail elsewhere (Garrigue et al., 1994; Saint-Mezard
et al., 2003). Mice were sensitized on day 0 and 1 on fur-shaven
flank at an irritant concentration of 0.5% of DNFB diluted in acetone
(25 ml). Five days later animals were challenged on each side of both
ears by applying a nonirritant concentration of 0.2% of DNFB in
acetone (10 ml). AfterB10 seconds, either AFC ranging from 0.002 to
2mg/20 ml in H2O was applied using a saturated cotton swab or
10 ml of Dex (16mg/20ml) in acetone was applied by pipette to both
the front and back surface of the experimental ears. Water was used
as the vehicle for AFC because preliminary experiments revealed
that acetone interfered with AFC inhibition of the DNFB challenge.
Positive and negative control groups received only H2O on both ears
after initially being challenged with DNFB.
Ear weight
Edema was measured 5.5. hours after treatment with TPA, 1 hour
after treatment with AA, or 24 hours after treatment with DNFB. The
mice were killed and the ears were removed. A 6mm dermal biopsy
punch was used to remove a uniform sample from each ear. Each
6mm ear punch was weighed using an analytical balance. For the
ACD experiments, ear thickness was measured before taking the
punch using a micrometer, and the thickness measurements were
well correlated with the mass of the punch. The average masses of
the punches from the vehicle-only treated ears and the punches from
ears treated with irritant were used, respectively, to define 0 and
100% inhibition of edema. Dose–response curves were generated by
fitting the data with the Hill, three-parameter equation using the
Sigma Plot software (Systat Software Inc., San Jose, CA), from which
the ED50 (potency) and maximum inhibition (activity) were
determined. Where the three-parameter fit gave a maximum
inhibition greater than 100% inhibition, the curves were instead fit
with the Hill equation with two parameters and with the maximum
inhibition fixed at 100%.
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MPO activity
MPO activity in tissue is a marker for neutrophil infiltration in
response to irritation (Bradley et al., 1982; Young et al., 1983;
De Young et al., 1989; Rao et al., 1993; Graff et al., 1998). It was
assayed 24 hours after treatment with TPA or 1 hour after treatment
with AA. The 6mm punch of ear tissue was snap-frozen in liquid
nitrogen and stored at 801C. MPO activity was assayed based on
methods described previously (Bradley et al., 1982; Graff et al.,
1998). MPO was liberated from each ear punch by homogenizing for
approximately 20 seconds in 400ml of 0.5% hexadecyltrimethyl-
ammonium bromide in 50mM potassium phosphate buffer (pH 6.0)
using a 7mm saw-tooth homogenizer. For the interval dependence,
a Fast Prep 24 (MP Biomedicals, Solon, OH) was used for two cycles
of 45 seconds with Lysing Matrix A instead of the saw-tooth
homogenizer. After centrifuging for 5minutes at 35,000 g, aliquots
of the supernatant (1–10 ml) were assayed for MPO, activity using a
model EL 340 96-well plate reader (BioTek Instruments, Winooski,
VT). The assay buffer contained 0.167mg/ml o-dianisidine di-
hydrochloride and 0.0005% H2O2 in 50mM phosphate buffer (pH 6.0).
The H2O2 was added to the o-dianisidine dihydrochloride solution
exactly 2minutes before each assay to ensure maximum reprodu-
cibility (C Cataisson, personal communication). The change in
absorbance at 450 nm in a 200 ml volume was measured every
7.5 seconds, and the data covering the first 45 seconds were fit to a
line and slope used as the activity value after correction for the
volume assayed. Each sample was assayed at least in triplicate. The
volume assayed for each sample adjusted to ensure that the reaction
was linear during the assay, but for comparison and calculations, all
data were converted to the activity per 10ml of supernatant (Table 2).
The liquid path length in the microplate well is about 0.5 cm, and 1U
of MPO activity corresponds to the oxidation of 1mmol of o-dianisidine
dihydrochloride per minute assuming De¼ 1.01 104M1 cm1
(Graff et al., 1998), so an observed activity of 100mAu/minute per
10 ml assay corresponds to approximately 1.5U of MPO enzyme per
6mm punch. Dose–response curves were generated by fitting the
data with the Hill, three-parameter equation using the Sigma Plot
software, from which the ED50 and maximum inhibition were
determined. Where the three-parameter fit gave a maximum
inhibition greater than 100% inhibition, the curves were instead fit
with the Hill equation with two parameters and with the maximum
inhibition fixed at 100%.
Histological analysis
Mice were killed, ears removed, and a 6mm dermal punch of the ear
tissue was prepared for histological analysis by fixing with 10%
formalin in phosphate-buffered saline (Reynolds et al., 1997).
Parafin-embedded, cross-sectioned samples were stained with
hematotoxalin and eosin for microscopy (Goode Histolab, New
Brunswick, NJ).
To count the neutrophils present during the initial inflammatory
events, mice were killed 5.5 hours after treatment. Neutrophils
identified in micrographs by their distinctive nuclear morphologies
in three  400 fields per ear section were manually counted by a
blinded observer.
For epidermal thickness, mice were killed 24 hours after
treatment. Treatments were applied to the mice using the contra-
lateral ear as an internal control. A control group received only
acetone on one ear and 800mg/20ml AFC on the other ear, and in the
experimental group the vehicle ear was irritated with 0.8 mg/20ml
TPA, whereas the treatment ear received 0.8 mg/20 ml TPA with
800mg/20 ml AFC. Digital micrographs of the stained sections were
collected using an Eclipse E-800 (Nikon Instruments, Melville, NY)
microscope, digital camera (model RTE/CCD-1517-K/1, Princeton
Instruments, Trenton, NJ), and MetaMorph software (Molecular
Devices Corp., Sunnyvale, CA). The epidermal thickness at
randomly selected points along both ear surfaces was measured
using ImageJ software (Abramoff et al., 2004) by two investigators
blinded to the identity of the samples.
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Figure S1. Inhibition by AFC of AA-induced edema.
Figure S2. Inhibition by AFC of AA-induced MPO activity.
Figure S3. Effect of AGC on TPA-induced MPO activity.
Figure S4. Inhibition by indomethacin of TPA-induced MPO.
REFERENCES
Abbinante-Nissen JM, Simpson LG, Leikauf GD (1995) Corticosteroids
increase secretory leukocyte protease inhibitor transcript levels in airway
epithelial cells. Am J Physiol 268:L601–6
Abramoff MD, Magelhaes PJ, Ram SJ (2004) Image Processing with Image.
J Biophotonics Int 11:36–42
Ahmad M, Zhang Y, Zhang Y, Papharalambus C, Alexander RW (2002) Role
of isoprenylcysteine carboxyl methyltransferase in tumor necrosis factor-
alpha stimulation of expression of vascular cell adhesion molecule-1 in
endothelial cells. Arterioscler Thromb Vasc Biol 22:759–64
Bargatze RF, Butcher EC (1993) Rapid G protein-regulated activation event
involved in lymphocyte binding to high endothelial venules. J Exp Med
178:367–72
Beato M, Herrlich P, Schutz G (1995) Steroid hormone receptors: many actors
in search of a plot. Cell 83:851–7
Belvisi MG, Brown TJ, Wicks S, Foster ML (2001a) New glucocorticosteroids
with an improved therapeutic ratio? Pulm Pharmacol Ther 14:221–7
Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P et al.
(2001b) Therapeutic benefit of a dissociated glucocorticoid and the
relevance of in vitro separation of transrepression from transactivation
activity. J Immunol 166:1975–82
Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of
cutaneous inflammation: estimation of neutrophil content with an
enzyme marker. J Invest Dermatol 78:206–9
Cacalano G, Lee J, Kikly K, Ryan AM, Pitts-Meek S, Hultgren B et al. (1994)
Neutrophil and B cell expansion in mice that lack the murine IL-8
receptor homolog. Science 265:682–4
Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J,
Koenderman L et al. (1995) Negative cross-talk between RelA and the
glucocorticoid receptor: a possible mechanism for the antiinflammatory
action of glucocorticoids. Mol Endocrinol 9:401–12
Carlson RP, O’Neill-Davis L, Chang J, Lewis AJ (1985) Modulation of mouse
ear edema by cyclooxygenase and lipoxygenase inhibitors and other
pharmacologic agents. Agents Actions 17:197–204
652 Journal of Investigative Dermatology (2008), Volume 128
JS Gordon et al.
AFC Inhibits Acute Skin Inflammation in the Mouse
Casey PJ, Solski PA, Der CJ, Buss JE (1989) p21ras is modified by a farnesyl
isoprenoid. Proc Natl Acad Sci USA 86:8323–7
Cataisson C, Joseloff E, Murillas R, Wang A, Atwell C, Torgerson S et al.
(2003) Activation of cutaneous protein kinase C alpha induces
keratinocyte apoptosis and intraepidermal inflammation by independent
signaling pathways. J Immunol 171:2703–13
Cataisson C, Pearson AJ, Torgerson S, Nedospasov SA, Yuspa SH (2005)
Protein kinase C alpha-mediated chemotaxis of neutrophils requires NF-
kappa B activity but is independent of TNF alpha signaling in mouse skin
in vivo. J Immunol 174:1686–92
Cataisson C, Pearson AJ, Tsien MZ, Mascia F, Gao JL, Pastore S et al. (2006)
CXCR2 ligands and G-CSF mediate PKCalpha-induced intraepidermal
inflammation. J Clin Invest 116:2757–66
Clarke S (1988) Perspectives on the biological function and enzymology of
protein carboxyl methylation reactions in eucaryotic and procaryotic
cells. Adv Exp Med Biol 231:213–28
Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW et al.
(2003) A novel antiinflammatory maintains glucocorticoid efficacy with
reduced side effects. Mol Endocrinol 17:860–9
Crowle AJ (1975) Delayed hypersensitivity in the mouse. Adv Immunol
20:197–264
De Young LM, Kheifets JB, Ballaron SJ, Young JM (1989) Edema and cell
infiltration in the phorbol ester-treated mouse ear are temporally separate
and can be differentially modulated by pharmacologic agents. Agents
Actions 26:335–41
Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR (1990) Transcription
factor interactions: selectors of positive or negative regulation from a
single DNA element. Science 249:1266–72
Ding J, Lu DJ, Perez-Sala D, Ma YT, Maddox JF, Gilbert BA et al. (1994)
Farnesyl-L-cysteine analogs can inhibit or initiate superoxide release by
human neutrophils. J Biol Chem 269:16837–44
Dlugosz AA, Yuspa SH (1993) Coordinate changes in gene expression which
mark the spinous to granular cell transition in epidermis are regulated by
protein kinase C. J Cell Biol 120:217–25
Epstein WW, Lever D, Leining LM, Bruenger E, Rilling HC (1991)
Quantitation of prenylcysteines by a selective cleavage reaction. Proc
Natl Acad Sci USA 88:9668–70
Evans RM (1988) The steroid and thyroid hormone receptor superfamily.
Science 240:889–95
Ferreira SH, Moncada S, Vane JR (1971) Indomethacin and aspirin abolish
prostaglandin release from the spleen. Nat New Biol 231:237–9
Forsberg M, Druid P, Zheng L, Stendahl O, Sarndahl E (2003) Activation of
Rac2 and Cdc42 on Fc and complement receptor ligation in human
neutrophils. J Leukoc Biol 74:611–9
Garrigue JL, Nicolas JF, Fraginals R, Benezra C, Bour H, Schmitt D
(1994) Optimization of the mouse ear swelling test for in vivo and
in vitro studies of weak contact sensitizers. Contact Dermatitis 30:
231–237
Graff G, Gamache DA, Brady MT, Spellman JM, Yanni JM (1998) Improved
myeloperoxidase assay for quantitation of neutrophil influx in a rat
model of endotoxin-induced uveitis. J Pharmacol Toxicol Methods
39:169–78
Griffiths RJ, Wood BE, Li S, Blackham A (1988) Pharmacological modification
of 12-0-tetradecanoylphorbol-13-acetate induced inflammation and
epidermal cell proliferation in mouse skin. Agents Actions 25:344–51
Gronemeyer H (1992) Control of transcription activation by steroid hormone
receptors. FASEB J 6:2524–9
Gschwendt M, Kittstein W, Furstenberger G, Marks F (1984) The mouse ear
edema: a quantitatively evaluable assay for tumor promoting compounds
and for inhibitors of tumor promotion. Cancer Lett 25:177–85
Hancock JF, Magee AI, Childs JE, Marshall CJ (1989) All ras proteins are
polyisoprenylated but only some are palmitoylated. Cell 57:1167–77
Hara T, Saito Y, Hirai T, Nakamura K, Nakao K, Katsuki M et al. (2005)
Deficiency of protein kinase Calpha in mice results in impairment
of epidermal hyperplasia and enhancement of tumor formation in
two-stage skin carcinogenesis. Cancer Res 65:7356–62
Huzoor-Akbar, Wang W, Kornhauser R, Volker C, Stock JB (1993) Protein
prenylcysteine analog inhibits agonist-receptor-mediated signal trans-
duction in human platelets. Proc Natl Acad Sci USA 90:868–72
Jansen AP, Dreckschmidt NE, Verwiebe EG, Wheeler DL, Oberley TD,
Verma AK (2001) Relation of the induction of epidermal ornithine
decarboxylase and hyperplasia to the different skin tumor-promotion
susceptibilities of protein kinase C alpha, -delta and -epsilon transgenic
mice. Int J Cancer 93:635–43
Jetten AM, George MA, Pettit GR, Herald CL, Rearick JI (1989) Action of
phorbol esters, bryostatins, and retinoic acid on cholesterol sulfate
synthesis: relation to the multistep process of differentiation in human
epidermal keratinocytes. J Invest Dermatol 93:108–15
Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H et al. (1990)
Antitumor promotion and antiinflammation: down-modulation of AP-1
(Fos/Jun) activity by glucocorticoid hormone. Cell 62:1189–204
Kostenis E (2004) A glance at G-protein-coupled receptors for lipid mediators:
a growing receptor family with remarkably diverse ligands. Pharmacol
Ther 102:243–57
Kotyuk B, Raychaudhuri A, DiPasquale G (1993) Effect of anti-inflammatory
compounds on edema formation and myeloperoxidase activity in the
arachidonic acid-induced ear model in the mouse. Agents Actions
39:C46–8
Kulke R, Bornscheuer E, Schluter C, Bartels J, Rowert J, Sticherling M et al.
(1998) The CXC receptor 2 is overexpressed in psoriatic epidermis.
J Invest Dermatol 110:90–4
Laudanna C, Campbell JJ, Butcher EC (1996) Role of Rho in chemoattractant-
activated leukocyte adhesion through integrins. Science 271:981–3
Levine SJ, Benfield T, Shelhamer JH (1996) Corticosteroids induce intracel-
lular interleukin-1 receptor antagonist type I expression by a human
airway epithelial cell line. Am J Respir Cell Mol Biol 15:245–51
Liu WS, Heckman CA (1998) The sevenfold way of PKC regulation. Cell
Signal 10:529–42
Lu JY, Hofmann SL (2006) Thematic review series: lipid posttranslational
modifications. Lysosomal metabolism of lipid-modified proteins. J Lipid
Res 47:1352–7
Lucibello FC, Slater EP, Jooss KU, Beato M, Muller R (1990) Mutual
transrepression of Fos and the glucocorticoid receptor: involvement
of a functional domain in Fos which is absent in FosB. EMBO J 9:
2827–34
Mackie AE, Bye A (2000) The relationship between systemic exposure to
fluticasone propionate and cortisol reduction in healthy male volunteers.
Clin Pharmacokinet 39(Suppl 1):47–54
Michaelidou AS, Hadjipavlou-Litina D (2005) Nonsteroidal anti-inflammatory
drugs (NSAIDs): a comparative QSAR study. Chem Rev 105:
3235–3271
Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T et al.
(1994) Novel mechanism of glucocorticoid-mediated gene repression.
Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin
8 gene repression. J Biol Chem 269:13289–95
Opas EE, Bonney RJ, Humes JL (1985) Prostaglandin and leukotriene
synthesis in mouse ears inflamed by arachidonic acid. J Invest Dermatol
84:253–6
Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K (1991) Properties of
the novel proinflammatory supergene "intercrine" cytokine family. Annu
Rev Immunol 9:617–48
Philips MR, Pillinger MH, Staud R, Volker C, Rosenfeld MG, Weissmann G
et al. (1993) Carboxyl methylation of Ras-related proteins during signal
transduction in neutrophils. Science 259:977–80
Rao TS, Currie JL, Shaffer AF, Isakson PC (1993) Comparative evaluation of
arachidonic acid (AA)- and tetradecanoylphorbol acetate (TPA)-induced
dermal inflammation. Inflammation 17:723–41
Ray A, Prefontaine KE (1994) Physical association and functional antagonism
between the p65 subunit of transcription factor NF-kappa B and the
glucocorticoid receptor. Proc Natl Acad Sci USA 91:752–6
Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P et al.
(2001) Repression of inflammatory responses in the absence of DNA
binding by the glucocorticoid receptor. EMBO J 20:7168–73
www.jidonline.org 653
JS Gordon et al.
AFC Inhibits Acute Skin Inflammation in the Mouse
Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS (1990) Inhibition of
purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides.
Cell 62:81–8
Reynolds NJ, McCombie SW, Shankar BB, Bishop WR, Fisher GJ (1997) SCH
47112, a novel staurosporine derivative, inhibits 12-O-tetradecanoyl-
phorbol-13-acetate-induced inflammation and epidermal hyperplasia in
hairless mouse skin. Arch Dermatol Res 289:540–6
Saint-Mezard P, Krasteva M, Chavagnac C, Bosset S, Akiba H, Kehren J et al.
(2003) Afferent and efferent phases of allergic contact dermatitis (ACD)
can be induced after a single skin contact with haptens: evidence using a
mouse model of primary ACD. J Invest Dermatol 120:641–7
Santangelo F (2003) Intracellular thiol concentration modulating inflamma-
tory response: influence on the regulation of cell functions through
cysteine prodrug approach. Curr Med Chem 10:2599–610
Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N et al.
(2004) Dissociation of transactivation from transrepression by a selective
glucocorticoid receptor agonist leads to separation of therapeutic effects
from side effects. Proc Natl Acad Sci USA 101:227–32
Schafer-Korting M, Kleuser B, Ahmed M, Holtje HD, Korting HC (2005)
Glucocorticoids for human skin: new aspects of the mechanism of
action. Skin Pharmacol Physiol 18:103–14
Scheer A, Gierschik P (1993) Farnesylcysteine analogues inhibit chemotactic
peptide receptor-mediated G-protein activation in human HL-60
granulocyte membranes. FEBS Lett 319:110–4
Schottelius AJ, Giesen C, Asadullah K, Fierro IM, Colgan SP, Bauman J et al.
(2002) An aspirin-triggered lipoxin A4 stable analog displays a unique
topical anti-inflammatory profile. J Immunol 169:7063–70
Schu¨le R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N et al. (1990)
Functional antagonism between oncoprotein c-Jun and the glucocorti-
coid receptor. Cell 62:1217–26
Smith JB, Willis AL (1971) Aspirin selectively inhibits prostaglandin
production in human platelets. Nat New Biol 231:235–7
Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, Poston RN (1996) Expression
of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist
(IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med
154:1061–6
Stimmel JB, Deschenes RJ, Volker C, Stock J, Clarke S (1990) Evidence for an
S-farnesylcysteine methyl ester at the carboxyl terminus of the
Saccharomyces cerevisiae RAS2 protein. Biochemistry (Mosc) 29:9651–9
Tramposch KM (1999) Skin inflamation. In In vivo Models of Inflammation.
(Morgan DW, Marshall LA eds), Birkha¨user Verlag: Basel, pp 179–204
Van Arman CG (1974) Anti-inflammatory drugs. Clin Pharmacol Ther
16:900–4
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action
for aspirin-like drugs. Nat New Biol 231:232–5
Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C et al.
(1997) Synthetic glucocorticoids that dissociate transactivation and AP-1
transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol
11:1245–55
Volker C, Lane P, Kwee C, Johnson M, Stock J (1991a) A single activity
carboxyl methylates both farnesyl and geranylgeranyl cysteine residues.
FEBS Lett 295:189–94
Volker C, Miller RA, Stock JB (1990) S-Farnesylcysteine methyltransferase in
bovine brain. Methods 1:283–7
Volker C, Miller RA, McCleary WR, Rao A, Poenie M, Backer JM et al.
(1991b) Effects of farnesylcysteine analogs on protein carboxyl methyl-
ation and signal transduction. J Biol Chem 266:21515–22
Volker CR (1995) Carboxyl methylation at C-terminal S-prenylcysteine
residues. Department of Chemistry, Princeton University PhD Thesis.
571pp
Wang HQ, Smart RC (1999) Overexpression of protein kinase C-alpha
in the epidermis of transgenic mice results in striking alterations
in phorbol ester-induced inflammation and COX-2, MIP-2 and
TNF-alpha expression but not tumor promotion. J Cell Sci 112(Part 20):
3497–506
Wu D, LaRosa GJ, Simon MI (1993) G protein-coupled signal transduction
pathways for interleukin-8. Science 261:101–3
Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J et al.
(1990) Transcriptional interference between c-Jun and the glucocorticoid
receptor: mutual inhibition of DNA binding due to direct protein–protein
interaction. Cell 62:1205–15
Young JM, Spires DA, Bedord CJ, Wagner B, Ballaron SJ, De Young LM (1984)
The mouse ear inflammatory response to topical arachidonic acid.
J Invest Dermatol 82:367–71
Young JM, Wagner BM, Spires DA (1983) Tachyphylaxis in 12-O-
tetradecanoylphorbol acetate- and arachidonic acid-induced ear edema.
J Invest Dermatol 80:48–52
Zhang L, Tschantz WR, Casey PJ (1997a) Isolation and characterization of a
prenylcysteine lyase from bovine brain. J Biol Chem 272:23354–9
Zhang Z, Zimonjic DB, Popescu NC, Wang N, Gerhard DS, Stone EM
et al. (1997b) Human uteroglobin gene: structure, subchromosomal
localization, and polymorphism. DNA Cell Biol 16:73–83
654 Journal of Investigative Dermatology (2008), Volume 128
JS Gordon et al.
AFC Inhibits Acute Skin Inflammation in the Mouse
